MCTS1 promotes the development of lung adenocarcinoma by regulating E2F1 expression

Gao,Cun; Dong,Rui; Li,Yongmeng; Liang,Jinghui; Tian,Hui

doi:10.3892/ol.2021.12792

MCTS1 promotes the development of lung adenocarcinoma by regulating E2F1 expression

Authors:
- Cun Gao
- Rui Dong
- Yongmeng Li
- Jinghui Liang
- Hui Tian
View Affiliations

Affiliations: Department of Thoracic Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: May 17, 2021 https://doi.org/10.3892/ol.2021.12792
Article Number: 531
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer that results in the majority of cancer‑associated mortality. Multiple copies in T‑cell lymphoma‑1 (MCTS1) is an oncogene that is expressed at high levels in several types of cancer tissues. However, its exact role and pathomechanism in the development of LUAD remains unknown. Reverse transcription‑quantitative PCR analysis was performed to detect MCTS1 expression. Immunohistochemistry analysis was performed to detect MCTS1 expression in LUAD tissues and normal tissues. The MTT, colony formation, EdU, flow cytometry, wound healing and Transwell assays were performed to assess the proliferation, apoptosis, migration and invasion of LUAD cells. Western blot analysis was performed to detect protein expression levels. The present study aimed to investigate the effects of MCTS1 on the progression of LUAD and the potential mechanisms underlying its effects. The results demonstrated that MCTS1 expression was upregulated in LUAD tissues and cells, which was associated with an unfavorable outcome in patients with LUAD. MCTS1 knockdown inhibited LUAD progression by suppressing cell viability and motility, and promoting apoptosis. In addition, E2F1 protein expression was attenuated following MCTS1 knockdown. The silencing MCTS1‑induced inhibitory effect on LUAD malignancy was reversed following overexpression of E2F1 by modulating the c‑Myc signaling pathway. Taken together, the results of the present study suggest that MCTS1 facilitates cell proliferation and migration, and suppresses apoptosis of LUAD cells by regulating E2F1 expression and the c‑Myc signaling pathway.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Tan WL, Jain A, Takano A, Newell EW, Iyer NG, Lim WT, Tan EH, Zhai W, Hillmer AM, Tam WL and Tan DSW: Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol. 17:e347–e362. 2016. View Article : Google Scholar : PubMed/NCBI
3	Zhang H, Guo L and Chen J: Rationale for lung adenocarcinoma prevention and drug development based on molecular biology during carcinogenesis. Onco Targets Ther. 13:3085–3091. 2020. View Article : Google Scholar : PubMed/NCBI
4	Ettinger DS: Ten years of progress in non-small cell lung cancer. J Natl Compr Canc Netw. 10:292–295. 2012. View Article : Google Scholar : PubMed/NCBI
5	Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, Lee JI, Suh YL, Ku BM, Eum HH, et al: Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 11:22852020. View Article : Google Scholar : PubMed/NCBI
6	Mizuno K, Mataki H, Seki N, Kumamoto T, Kamikawaji K and Inoue H: MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis. J Hum Genet. 62:57–65. 2017. View Article : Google Scholar : PubMed/NCBI
7	Prosniak M, Dierov J, Okami K, Tilton B, Jameson B, Sawaya BE and Gartenhaus RB: A novel candidate oncogene, MCT-1, is involved in cell cycle progression. Cancer Res. 58:4233–4237. 1998.PubMed/NCBI
8	Li Y, Wang B, Gui S and Ji J: Multiple copies in T-cell malignancy 1 (MCT-1) promotes the stemness of non-small cell lung cancer cells via activating Interleukin-6 (IL-6) signaling through suppressing MiR-34a expression. Med Sci Monit. 25:10198–10204. 2019. View Article : Google Scholar : PubMed/NCBI
9	Shih HJ, Chen HH, Chen YA, Wu MH, Liou GG, Chang WW, Chen L, Wang LH and Hsu HL: Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity. Oncotarget. 3:1401–1415. 2012. View Article : Google Scholar : PubMed/NCBI
10	Wu MH, Chen YA, Chen HH, Chang KW, Chang IS, Wang LH and Hsu HL: MCT-1 expression and PTEN deficiency synergistically promote neoplastic multinucleation through the Src/p190B signaling activation. Oncogene. 33:5109–5120. 2014. View Article : Google Scholar : PubMed/NCBI
11	Levenson AS, Thurn KE, Simons LA, Veliceasa D, Jarrett J, Osipo C, Jordan VC, Volpert OV, Satcher RL Jr and Gartenhaus RB: MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. Cancer Res. 65:10651–10656. 2005. View Article : Google Scholar : PubMed/NCBI
12	Dierov J, Prosniak M, Gallia G and Gartenhaus RB: Increased G1 cyclin/cdk activity in cells overexpressing the candidate oncogene, MCT-1. J Cell Biochem. 74:544–550. 1999. View Article : Google Scholar : PubMed/NCBI
13	Weng YS, Tseng HY, Chen YA, Shen PC, Al Haq AT, Chen LM, Tung YC and Hsu HL: MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Mol Cancer. 18:422019. View Article : Google Scholar : PubMed/NCBI
14	Burkhart DL and Sage J: Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 8:671–682. 2008. View Article : Google Scholar : PubMed/NCBI
15	Chen HZ, Tsai SY and Leone G: Emerging roles of E2Fs in cancer: An exit from cell cycle control. Nat Rev Cancer. 9:785–797. 2009. View Article : Google Scholar : PubMed/NCBI
16	Wang T, Chen X, Qiao W, Kong L, Sun D and Li Z: Transcription factor E2F1 promotes EMT by regulating ZEB2 in small cell lung cancer. BMC Cancer. 17:7192017. View Article : Google Scholar : PubMed/NCBI
17	Singh S, Yennamalli RM, Gupta M and Changotra H: Identification of nsSNPs of transcription factor E2F1 predisposing individuals to lung cancer and head and neck cancer. Mutat Res. 821:1117042020. View Article : Google Scholar : PubMed/NCBI
18	Farra R, Grassi G, Tonon F, Abrami M, Grassi M, Pozzato G, Fiotti N, Forte G and Dapas B: The role of the transcription factor E2F1 in hepatocellular carcinoma. Curr Drug Deliv. 14:272–281. 2017.PubMed/NCBI
19	Farra R, Dapas B, Grassi M, Benedetti F and Grassi G: E2F1 as a molecular drug target in ovarian cancer. Expert Opin Ther Targets. 23:161–164. 2019. View Article : Google Scholar : PubMed/NCBI
20	Bi XC, Pu XY, Liu JM and Huang S: Effect of transcription factor E2F1 expression on the invasion of prostate cancer. Zhonghua Yi Xue Za Zhi. 97:2856–2859. 2017.(In Chinese). PubMed/NCBI
21	Tsantoulis PK and Gorgoulis VG: Involvement of E2F transcription factor family in cancer. Eur J Cancer. 41:2403–2414. 2005. View Article : Google Scholar : PubMed/NCBI
22	Yin J, Fu W, Dai L, Jiang Z, Liao H, Chen W, Pan L and Zhao J: ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1. Sci Rep. 7:44302017. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
25	Yu G, Wang LG, Han Y and He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
26	Porebska I, Wyrodek E, Kosacka M, Adamiak J, Jankowska R and Harłozińska-Szmyrka A: Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer. In Vivo. 20:599–604. 2006.PubMed/NCBI
27	Reinert LS, Shi B, Nandi S, Mazan-Mamczarz K, Vitolo M, Bachman KE, He H and Gartenhaus RB: MCT-1 protein interacts with the cap complex and modulates messenger RNA translational profiles. Cancer Res. 66:8994–9001. 2006. View Article : Google Scholar : PubMed/NCBI
28	Guo C, Huang T, Wang QH, Li H, Khanal A, Kang EH, Zhang W, Niu HT, Dong Z and Cao YW: Monocarboxylate transporter 1 and monocarboxylate transporter 4 in cancer-endothelial co-culturing microenvironments promote proliferation, migration, and invasion of renal cancer cells. Cancer Cell Int. 19:1702019. View Article : Google Scholar : PubMed/NCBI
29	Stewart MJ, Litz-Jackson S, Burgess GS, Williamson EA, Leibowitz DS and Boswell HS: Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells. Leukemia. 9:1499–1507. 1995.PubMed/NCBI
30	Matsumura I, Tanaka H and Kanakura Y: E2F1 and c-Myc in cell growth and death. Cell Cycle. 2:333–338. 2003. View Article : Google Scholar : PubMed/NCBI
31	Wei S, Zhang ZY, Fu SL, Xie JG, Liu XS, Xu YJ, Zhao JP and Xiong WN: Correction to: Hsa-miR-623 suppresses tumor progression in human lung adenocarcinoma. Cell Death Dis. 9:8292018. View Article : Google Scholar : PubMed/NCBI
32	Xiong DD, Li ZY, Liang L, He RQ, Ma FC, Luo DZ, Hu XH and Chen G: The LncRNA NEAT1 accelerates lung adenocarcinoma deterioration and Binds to Mir-193a-3p as a competitive endogenous RNA. Cell Physiol Biochem. 48:905–918. 2018. View Article : Google Scholar : PubMed/NCBI
33	Martin LW, D'Cunha J, Wang X, Herzan D, Gu L, Abraham N, Demmy TL, Detterbeck FC, Groth SS, Harpole DH, et al: Detection of occult micrometastases in patients with clinical stage I non-small-cell lung cancer: A prospective analysis of mature results of CALGB 9761 (Alliance). J Clin Oncol. 34:1484–1491. 2016. View Article : Google Scholar : PubMed/NCBI
34	Ali SA, Justilien V, Jamieson L, Murray NR and Fields AP: Protein Kinase Cι Drives a NOTCH3-dependent Stem-like phenotype in mutant KRAS lung adenocarcinoma. Cancer Cell. 29:367–378. 2016. View Article : Google Scholar : PubMed/NCBI
35	Calvayrac O, Pradines A, Pons E, Mazières J and Guibert N: Molecular biomarkers for lung adenocarcinoma. Eur Respir J. 49:16017342017. View Article : Google Scholar : PubMed/NCBI
36	Kasiappan R, Shih HJ, Chu KL, Chen WT, Liu HP, Huang SF, Choy CO, Shu CL, Din R, Chu JS and Hsu HL: Loss of p53 and MCT-1 overexpression synergistically promote chromosome instability and tumorigenicity. Mol Cancer Res. 7:536–548. 2009. View Article : Google Scholar : PubMed/NCBI
37	Sprowl-Tanio S, Habowski AN, Pate KT, McQuade MM, Wang K, Edwards RA, Grun F, Lyou Y and Waterman ML: Lactate/pyruvate transporter MCT-1 is a direct Wnt target that confers sensitivity to 3-bromopyruvate in colon cancer. Cancer Metab. 4:202016. View Article : Google Scholar : PubMed/NCBI
38	Giatromanolaki A, Koukourakis MI, Koutsopoulos A, Mendrinos S and Sivridis E: The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biol Ther. 13:1284–1289. 2012. View Article : Google Scholar : PubMed/NCBI
39	Shi B, Hsu HL, Evens AM, Gordon LI and Gartenhaus RB: Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies. Blood. 102:297–302. 2003. View Article : Google Scholar : PubMed/NCBI
40	Kasiappan R, Shih HJ, Wu MH, Choy C, Lin TD, Chen L and Hsu HL: The antagonism between MCT-1 and p53 affects the tumorigenic outcomes. Mol Cancer. 9:3112010. View Article : Google Scholar : PubMed/NCBI
41	Huang HK, Lee SY, Huang SF, Lin YS, Chao SC, Huang SF, Lee SC, Cheng TH, Loh SH and Tsai YT: Isoorientin decreases cell migration via decreasing functional activity and molecular expression of proton-linked monocarboxylate transporters in human lung cancer cells. Am J Chin Med. 48:201–222. 2020. View Article : Google Scholar : PubMed/NCBI
42	Aravind L and Koonin EV: Novel predicted RNA-binding domains associated with the translation machinery. J Mol Evol. 48:291–302. 1999. View Article : Google Scholar : PubMed/NCBI
43	Johannsson S, Neumann P and Ficner R: Crystal structure of the human tRNA guanine transglycosylase catalytic subunit QTRT1. Biomolecules. 8:812018. View Article : Google Scholar : PubMed/NCBI
44	Fleischer TC, Weaver CM, McAfee KJ, Jennings JL and Link AJ: Systematic identification and functional screens of uncharacterized proteins associated with eukaryotic ribosomal complexes. Genes Dev. 20:1294–1307. 2006. View Article : Google Scholar : PubMed/NCBI
45	Holcik M and Sonenberg N: Translational control in stress and apoptosis. Nat Rev Mol Cell Biol. 6:318–327. 2005. View Article : Google Scholar : PubMed/NCBI
46	Andersen G, Busso D, Poterszman A, Hwang JR, Wurtz JM, Ripp R, Thierry JC, Egly JM and Moras D: The structure of cyclin H: Common mode of kinase activation and specific features. EMBO J. 16:958–967. 1997. View Article : Google Scholar : PubMed/NCBI
47	Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC and Li F: The c-Myc target gene network. Semin Cancer Biol. 16:253–264. 2006. View Article : Google Scholar : PubMed/NCBI
48	Bell LA and Ryan KM: Life and death decisions by E2F-1. Cell Death Differ. 11:137–142. 2004. View Article : Google Scholar : PubMed/NCBI
49	Wu Z, Zheng S and Yu Q: The E2F family and the role of E2F1 in apoptosis. Int J Biochem Cell Biol. 41:2389–2397. 2009. View Article : Google Scholar : PubMed/NCBI